Healthy Q3; all set for recovery in core areas
21/10/21 -"Roche reported healthy Q3 sales numbers (8% CER growth), with the robust performance in Diagnostics being complemented by a strong contribution from COVID-19 treatment initiatives, and recovering ..."
Pages
70
Language
English
Published on
21/10/21
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...